Cellular Biomedicine Group Inc. | Ownership
Companies that own Cellular Biomedicine Group Inc.
Shanghai Securities Co., Ltd. (Investment Management)
1,719,324
10.14%
6,404
71.15%
03/09/2018
BlackRock Fund Advisors
541,885
3.2%
454,163
0%
06/30/2018
The Vanguard Group, Inc.
156,947
0.93%
17,137
0%
06/30/2018
SSgA Funds Management, Inc.
141,664
0.84%
130,335
0%
06/30/2018
Geode Capital Management LLC
92,023
0.54%
33,938
0%
06/30/2018
Northern Trust Investments, Inc.
81,758
0.48%
43,778
0%
06/30/2018
Bridgeway Capital Management, Inc.
69,100
0.41%
0
0.01%
06/30/2018
BlackRock Investment Management LLC
31,431
0.19%
29,538
0%
06/30/2018
The Bank of New York Mellon Corp. (Investment Management)
29,394
0.17%
19,766
0%
06/30/2018
Morgan Stanley & Co. LLC
24,743
0.15%
10,805
0%
06/30/2018
| Address |
1345 Avenue of Americas
New York New York 10105
United States
|
|
Employees
|
- |
| Website |
http://www.cellbiomedgroup.com |
| Updated |
07/08/2019 |
| Cellular Biomedicine Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new treatments for cancerous and degenerative diseases utilizing proprietary cell-based technologies. Its technology includes immune system therapy for treatment of cancer indications and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases The company was founded in 2009 and is headquartered in Cupertino, CA. . |
